FDA Drug Shortage: Bumetanide Injection (Current)

Bumetanide injection remains in active shortage as of February 2025, according to FDA's Drug Shortages Database. The shortage affects a loop diuretic used primarily in hospital settings to treat edema associated with congestive heart failure, hepatic cirrhosis, and renal disease. Wholesale drug distributors and hospital group purchasing organizations should verify alternative sourcing arrangements and monitor allocation protocols from manufacturers still supplying the product.

Regulatory Context

FDA maintains the Drug Shortages Database under authority granted by the Food and Drug Administration Safety and Innovation Act (FDASIA) of 2012 and expanded by the FDA Reauthorization Act (FDARA) of 2017. Under 21 U.S.C. § 356c, manufacturers must notify FDA at least six months in advance of a potential discontinuation or interruption in production of certain drugs, including those on the shortage list. Bumetanide injection qualifies as a medically necessary drug under this statute due to lack of therapeutic alternatives in certain clinical scenarios.

The shortage designation triggers specific obligations for wholesale distributors under state pharmacy laws. In states with anti-price gouging statutes—including California (Business and Professions Code § 4169), New York (Public Health Law § 281-a), and Florida (Florida Statutes § 501.160)—distributors face restrictions on markup percentages during declared shortages. Violation of these provisions can result in license suspension or civil penalties ranging from $10,000 to $1 million per occurrence, depending on jurisdiction.

Shortage Details

FDA classified the bumetanide injection shortage as current with no estimated resolution date published. The shortage stems from manufacturing delays reported by multiple suppliers. As of the most recent FDA database update, no manufacturers have provided FDA with a restart date for normal production levels.

Bumetanide injection is typically supplied in 2 mL and 10 mL vials containing 0.25 mg/mL. The product requires storage at controlled room temperature (20-25°C) and is not subject to cold chain requirements. However, its classification as a hospital-only product means distribution channels are more limited than retail pharmaceuticals—most volume moves through hospital GPOs and specialty acute-care distributors rather than traditional wholesale channels.

FDA has not approved temporary importation of foreign-supply bumetanide to address the shortage, nor has the agency issued a guidance document authorizing compounding as an interim measure. This limits options for distributors attempting to maintain supply continuity.

Impact on Wholesale Distribution

Distributors holding existing bumetanide injection inventory must implement allocation protocols to ensure equitable distribution among customers. State boards of pharmacy in at least 18 states have issued guidance requiring wholesale distributors to allocate shortage drugs based on historical ordering patterns rather than accepting orders on a first-come basis. Failure to maintain documentation of allocation methodology exposes distributors to claims of unfair dealing during audits.

Trading partner verification under DSCSA (Drug Supply Chain Security Act) becomes more complex during shortages. Distributors may receive unsolicited offers from secondary sources claiming available bumetanide stock. Under 21 U.S.C. § 360eee-1(c)(4), wholesale distributors must verify that the product was purchased directly from the manufacturer, from an authorized distributor of record, or from another entity that meets the verification requirements. Enhanced due diligence is advisable when shortage conditions create financial incentives for diverted or counterfeit product to enter distribution. For detailed verification procedures, see the DSCSA compliance checklist for wholesale distributors.

3PLs managing hospital inventory on consignment should verify that their contracts address allocation rights during shortages. Many hospital agreements include force majeure clauses, but shortage designation alone does not typically qualify as an excusing event unless the contract explicitly references FDA shortage declarations. Distributors should document allocation decisions contemporaneously to support potential contract disputes.

What ColdChainCheck Data Shows

Of the 1,275 wholesale drug distributors and 3PLs tracked in ColdChainCheck's directory, 1,234 hold active FDA establishment registration—a baseline requirement for handling prescription drugs including bumetanide injection. However, only 63 entities hold NABP accreditation, the voluntary credential that requires enhanced due diligence protocols during supply chain disruptions. This 5% accreditation rate means most distributors in the database operate under state licensure alone, with no third-party verification of their shortage management procedures.

The average compliance score of 51/100 places the industry in the "fair" tier. During drug shortages, procurement teams typically tighten vendor qualification standards—entities in the "good" (281 distributors) and "excellent" (28 distributors) tiers may see increased demand as buyers concentrate purchases with higher-scoring trading partners. Conversely, the 38 entities in the "poor" tier and 9 in the "minimal" tier face heightened scrutiny. Distributors with recalls on record (73 entities) should expect additional verification requests when offering shortage products.

Practical Steps for Compliance Officers

• Verify current trading partners: Use the ColdChainCheck directory to confirm your bumetanide suppliers hold active state licenses in your jurisdiction and current FDA establishment registration. Filter by state to identify locally licensed alternatives if your primary source allocates supply.

• Document shortage protocols: If your organization sources from multiple distributors during shortages, document each entity's compliance posture before placing orders. Download compliance score reports for audit files—boards of pharmacy increasingly ask for trading partner verification records during shortage investigations.

• Monitor allocation fairness: If a distributor reports bumetanide unavailability but you suspect selective allocation, check whether they hold NABP accreditation. Accredited distributors must follow NABP's ethical standards, which prohibit preferential allocation based on payment terms. File allocation complaints with your state board if warranted.

• Flag secondary market offers: Unsolicited bumetanide offers during shortage conditions warrant enhanced due diligence. Cross-reference the offering entity against ColdChainCheck's recall database and verify their FDA registration status before initiating transaction history requests under DSCSA.

ColdChainCheck tracks FDA drug shortage declarations as part of ongoing compliance monitoring. For guidance on DSCSA verification requirements during supply disruptions, see our regulatory guides.

Disclaimer: This article is informational only and does not constitute legal or regulatory advice. Readers should verify current shortage status directly with FDA and consult qualified legal counsel regarding state-specific compliance obligations.